Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancer

Journal of Theoretical Biology

Volumn 223, Issue 2, 2003, Pages 205-213

  Kamb, Alexander ^a  

^a Deltagen Proteomics Incorporated   (United States)

Author keywords

Chemotherapy; Combinatorial; Genetic interaction; Model

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; DISEASE TREATMENT;

ARTICLE; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CHROMOSOME SEGREGATION; DNA REPLICATION; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; LETHALITY; PRIORITY JOURNAL; THEORETICAL MODEL;

EID: 0038581531     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5193(03)00087-0     Document Type: Article

References (24)

1. Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F., George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N., Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X., Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D., Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L., Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D., Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M., Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S., Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P., Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I., Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P., de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P., Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W., Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K., Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M., Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J., Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.et al. The genome sequence of Drosophila melanogaster. Science. 287:2000;2185-2195.
2. Balis F.M. The challenge of developing new therapies for childhood cancers. Oncologist. 2:1997;I-II.
3. Donehower L.A. The p53-deficient mouse. a model for basic and applied cancer studies Semin. Cancer Biol. 7:1996;269-278.
4. Driever W., Solnica-Krezel L., Schier A.F., Neuhauss S.C., Malicki J., Stemple D.L., Stainier D.Y., Zwartkruis F., Abdelilah S., Rangini Z., Belak J., Boggs C. A genetic screen for mutations affecting embryogenesis in zebrafish. Development. 123:1996;37-46.
5. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
6. Garber K. Cancer research. Taking garbage in, tossing cancer out? Science. 295:2002;612-613.
7. Guarente L. Synthetic enhancement in gene interaction. a genetic tool come of age Trends Genet. 9:1993;362-366.
8. Gupta P.K., Sahota A., Boyadjiev S.A., Bye S., Shao C., O'Neill J.P., Hunter T.C., Albertini R.J., Stambrook P.J., Tischfield J.A. High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Res. 57:1997;1188-1193.
9. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1997;1064-1068.
10. Hruban R.H., Yardley J.H., Donehower R.C., Boitnott J.K. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer. 63:1989;1944-1950.
11. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:2001;1111-1116.
12. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
13. Jordan A., Hadfield J.A., Lawrence N.J., McGown A.T. Tubulin as a target for anticancer drugs. agents which interact with the mitotic spindle Med. Res. Rev. 18:1998;259-296.
14. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51:1991;3075-3079.
15. Patel S., Keller B.A., Fisher L.M. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine. relevance for antitumor drug resistance in human cells Mol. Pharmacol. 57:2000;784-791.
16. Perucho M., Peinado M.A., Ionov Y., Casares S., Malkhosyan S., Stanbridge E. Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Cold Spring Harb. Symp. Quant. Biol. 59:1994;339-348.
17. Ross-Macdonald P., Coelho P.S., Roemer T., Agarwal S., Kumar A., Jansen R., Cheung K.H., Sheehan A., Symoniatis D., Umansky L., Heidtman M., Nelson F.K., Iwasaki H., Hager K., Gerstein M., Miller P., Roeder G.S., Snyder M. Large-scale analysis of the yeast genome by transposon tagging and gene disruption. Nature. 402:1999;413-418.
18. Sinicrope F.A., Hart J., Hsu H.A., Lemoine M., Michelassi F., Stephens L.C. Apoptotic and mitotic indices predict survival rates in lymph node- negative colon carcinomas. Clin Cancer Res. 5:1999;1793-1804.
19. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. P53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703-711.
20. Szafraniec K., Borts R.H., Korona R. Environmental stress and mutational load in diploid strains of the yeast Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA. 98:2001;1107-1112.
21. Tlsty T.D., Jonczyk P., White A., Sage M., Hall I., Schaefer D., Briot A., Livanos E., Roelofs H., Poulose B.et al. Loss of chromosomal integrity in neoplasia. Cold Spring Harb. Symp. Quant. Biol. 58:1993;645-654.
22. Tong A.H., Evangelista M., Parsons A.B., Xu H., Bader G.D., Page N., Robinson M., Raghibizadeh S., Hogue C.W., Bussey H., Andrews B., Tyers M., Boone C. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science. 294:2001;2364-2368.
23. Winzeler E.A., Shoemaker D.D., Astromoff A., Liang H., Anderson K., Andre B., Bangham R., Benito R., Boeke J.D., Bussey H., Chu A.M., Connelly C., Davis K., Dietrich F., Dow S.W., El Bakkoury M., Foury F., Friend S.H., Gentalen E., Giaever G., Hegemann J.H., Jones T., Laub M., Liao H., Davis R.W.et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science. 285:1999;901-906.
24. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.